Decreased T cell response to anti-CD2 in systemic lupus erythematosus and reversal by anti-CD28: Evidence for impaired T cell-accessory cell interaction

Arthritis and Rheumatism

Volumn 40, Issue 5, 1997, Pages 822-833

  Horwitz, David A ^a   Tang, Fu Lin ^a   Stimmler, Mary M ^a   Oki, Alan ^a   Gray, J Dixon ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD2 ANTIGEN; CD28 ANTIGEN; CD3 ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; INTERLEUKIN 10; LYMPHOCYTE SURFACE MARKER; MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY;

ACCESSORY CELL; ADULT; ANTIGEN EXPRESSION; ANTIGEN PRESENTING CELL; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; DISEASE ACTIVITY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; LYMPHOCYTE SUBPOPULATION; MAJOR CLINICAL STUDY; MALE; MONONUCLEAR CELL; PRIORITY JOURNAL; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE;

EID: 1842299353     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.1780400508     Document Type: Article

References (99)

1. Cohen PL, Litvin DA, Winfield JB: Association between endogenously activated T cells and immunoglobulin-secreting B cells in patients with active systemic lupus erythematosus. Arthritis Rheum 25:168-173, 1982
2. O'Dell JR, Bizar Schneebaum A, Kotzin BL: In vitro anti-histone antibody production by peripheral blood cells from patients with SLE. Clin Immunopathol 47:343-353, 1988
3. Gharavi AE, Chu J-L, Elkon KB: Autoantibodies to intracellular proteins in human systemic lupus erythematosus are not due to random polyclonal B cell activation. Arthritis Rheum 31:1337-1345, 1988
4. Via CS, Handwerger BS: B-cell and T-cell function in systemic lupus erythematosus. Curr Opin Rheumatol 5:570-574, 1993
5. Horwitz DA, Stohl W: Abnormalities in T lymphocytes. In, Dubois' Lupus Erythematosus. Fourth edition. Edited by DJ Wallace, BH Hahn. Philadelphia. Lea & Febiger, 1993
6. Tsokos GC: Overview of cellular immune function in systemic lupus erythematosus. In, Systemic Lupus Erythematosus. Edited by RG Lahita. New York. Churchill Livingstone. 1992
7. Horwitz DA: Impaired delayed hypersensitivity in systemic lupus erythematosus. Arthritis Rheum 15:353-359, 1972
8. Rosenthal CJ, Franklin EC: Depression of cellular-mediated immunity in systemic lupus erythematosus: relation to disease activity. Arthritis Rheum 18:207-217, 1975
9. Gottlieb AB, Lahita RG, Chiorazzi N, Kunkel HG: Immune function in systemic lupus erythematosus: impairment of in-vitro T-cell proliferation and in vivo antibody response to exogenous antigen. J Clin Invest 63:885-892, 1979
10. Horwitz DA, Garrett MA: Lymphocyte reactivity to mitogens in subjects with systemic lupus erythematosus, rheumatoid arthritis and scleroderma. Clin Exp Immunol 27:92-99, 1977
11. Stohl W: Impaired generation of polyclonal T cell-mediated cytotoxicity despite normal T cell proliferation in systemic lupus erythematosus. Clin Immunol Immunopathol 63:163-172, 1992
12. Dayal AK, Kammer GM: The T cell enigma in lupus. Arthritis Rheum 39:23-33, 1996
13. Murakawa Y, Takada S, Ueda Y, Suzuki N, Hoshino T, Sakane T: Characterization of T lymphocyte subpopulations responsible for deficient interleukin-2 activity in patients with systemic lupus erythematosus. J Immunol 134:187-195, 1985
14. Linker-Israeli M, Quismorio FP Jr, Horwitz DA: CD8+ lymphocytes from patients with systemic lupus erythematosus sustain, rather than suppress, spontaneous polyclonal IgG production and synergize with CD4+ cells to support autoantibody synthesis. Arthritis Rheum 33:1216-1225, 1990
15. Horwitz DA, Cousar JB: A relationship between impaired cellular immunity, humoral suppression of lymphocyte function, and severity of systemic lupus erythematosus. Am J Med 58:829-835, 1975
16. Winfield JB, Shaw M, Yamada A, Minota S: Subset specificity of antilymphocyte antibodies in systemic lupus erythematosus. II. Preferential reactivity with T4+ cells is associated with relative depletion of autologous T4+ cells. Arthritis Rheum 30:162-168, 1987
17. Markenson JA, Morgan JW, Lockshin MD, Joachim C, Winfield JB: Responses of fractionated cells from patients with systemic lupus erythematosus and normals to plant mitogen: evidence for a suppressor population of monocytes. Proc Soc Exp Biol Med 158:5-9, 1978
18. Boswelt J, Schur PH: Monocyte function in systemic lupus erythematosus. Clin Immunol Immunopathol 52:271-278, 1989
19. Via CS, Tsokos GC, Bermas B, Clerici M, Shearer GM: T cell-antigen presenting cell interactions in human systemic lupus erythematosus: evidence for heterogeneous expression of multiple defects. J Immunol 151:3914-3922, 1993
20. Linker-Israeli M, Bakke AC, Kitridou RC, Gendler S, Gillis S, Horwitz DA: Defective production of interleukin 1 and interleukin 2 in patients with systemic lupus erythematosus (SLE). J Immunol 130:2651-2655, 1983
21. Kabelitz D: Do CD2 and CD3-TCR T-cell activation pathways function independently? Immunol Today 11:44-47, 1990
22. Meur SC, Hussey RE, Fabbi M, Fox D, Acuto O, Fitzgerald KA, Hodgdon JC, Protentis JP, Schlossman SF, Reinherz EL: An alternative pathway of T cell activation: a functional role for the 50KD T11 sheep erythrocytc receptor protein. Cell 36:897-906, 1984
23. Sen J, Bossu P, Burakoff SJ, Abbas AK: T cell surface molecules regulating noncognate B lymphocyte activation: role of CD2 and LFA-1. J Immunol 148:1037-1042, 1992
24. Virella G, Rugeles MT, Hyman B, La Via M, Goust JM, Frankis M, Bierer BE: The interaction of CD2 with its LFA-3 ligand expressed by autologous erythrocytes results in enhancement of B cell responses. Cell Immunol 116:308-319, 1988
25. Miller GT, Hochman PS, Meier W, Tizard R, Bixler SA, Rosa MD, Wallner BP: Specific interaction of lymphocyte function-associated antigen 3 with CD2 can inhibit T cell responses. J Exp Med 178:211-222, 1993
26. Guckel B, Berek C, Lutz M, Altevogt P, Schirrmacher V, Kyewski BA: Anti-CD2 antibodies induce T cell unresponsiveness in vivo. J Exp Med 174:957-967, 1991
27. Gray JD, Hirokawa M, Horwitz DA: The role of transforming growth factor β in the generation of suppression: an interaction between CD8+ T and NK cells. J Exp Med 180:1937-1942, 1994
28. Gray JD, Hirokawa M, Ohtsuka K, Stimmler MM, Horwitz DA: Contrasting effects of anti-CD2 and anti-CD3 monoclonal anti- bodies in triggering an inhibitory circuit dependent on TGFβ provided by NK cells. Submitted for publication
29. Chavin KD, Qin L, Yon R, Lin J, Yagita H, Bromberg JS: Anti-CD2 mAbs suppress cytotoxic lymphocyte activity by the generation of Th2 suppressor cells and receptor blockade. J Immunol 152:3729-3739, 1994
30. Reder AT, Arnason BG, Maimone D, Rohwer-Nutter D: The function of the CD2 protein is abnormal in multiple sclerosis. J Autoimmun 4:479-491, 1991
31. Gerli R, Bertotto A, Agea E, Lanfrancone L, Cernetti C, Spinozzi F, Rambotti P: Basis for defective proliferation of peripheral blood T cells to anti-CD2 antibodies in primary Sjögren's syndrome. J Clin Invest 86:1870-1877, 1990
32. Fox DA, Millard JA, Treisman J, Zeldes W, Bergman A, Depper J, Dunne R, McCune WJ: Defective CD2 pathway T cell activation in systemic lupus erythematosus. Arthritis Rheum 34:561-571, 1991
33. June CH, Ledbetter JA, Linsley PS, Thompson CB: Role of the CD28 receptor in T-cell activation. Immunol Today 11:211-216, 1990
34. Van-Lier RA, Brouwer M, De-Groot ED, Kramer I, Aarden LA, Verhoeven AJ: T cell receptor/CD3 and CD28 use distinct intracellular signaling pathways. Eur J Immunol 21:1775-1778, 1991
35. Baroja ML, Lorre K, van Vaeck F, Ceuppens JL: The anti-T cell monoclonal antibody 9.3 (anti-CD28) provides a helper signal and bypasses the need for accessory cells in T cell activation with immobilized anti-CD3 and mitogens. Cell Immunol 120:205-217, 1989
36. Huet S, Wakasugi H, Sterkers G, Gilmour J, Tursz T, Boumsell L, Bernard A: T cell activation via CD2 (T, gp50): the role of accessory cells in activating resting T cells via CD2. J Immunol 137:1420-1428, 1986
37. Stohl W, Posnett DN, Chiorazzi N: Induction of T cell-dependent B cell differentiation by anti-CD3 monoclonal antibodies. J Immunol 138:1667-1673, 1987
38. Beverley PCL, Callard RE: Distinctive functional characteristics of human T lymphocytes defined by E rosetting or a monoclonal anti-T cell antibody. Eur J Immunol 11:329-334, 1981
39. Hansen JA, Martin PJ, Nowinski RC: Monoclonal antibodies identifying a novel T-cell antigen and la antigens of human lymphocytes. Immunogenetics 10:247-260, 1980
40. Lampson LA, Levy RH: Two populations of Ia-like molecules on a human B cell line. J Immunol 125:293-299, 1980
41. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, Schaller JG, Talal N, Winchester RJ: The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 25:1271-1277, 1982
42. Liang MH, Meenan RF, Cathcart ES, Schur PH: A screening strategy for population studies in systemic lupus erythematosus: series design. Arthritis Rheum 23:153-157, 1980
43. Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH, and The Committee on Prognosis Studies in SLE: Derivation of the SLEDAI: a disease activity index for lupus patients. Arthritis Rheum 35:630-640, 1992
44. Hirokawa M, Gray JD, Takahashi T, Horwitz DA: Human resting B lymphocytes serve as accessory cells for anti-CD2 induced T cell activation. J Immunol 149:1859-1866, 1992
45. Santiago-Schwartz F, Bakke AC, Woodward JC, O'Brien RL, Horwitz DA: Further characterization of low density mononuclear cells: FACS-assisted analysis of human MLR stimulators. J Immunol 134:779-785, 1985
46. Llorente L, Richaud-Patin Y, Wijdenes J, Alcocer-Varela J, Maillot MC, Durand-Gasselin I, Fourrier BM, Galanaud P, Emilie D: Spontaneous production of interleukin-10 by B lymphocytes and monocytes in systemic lupus erythematosus. Eur Cytokine Netw 4:421-427, 1993
47. Hagiwara E, Gourley MF, Lee S, Klinman DM: Disease severity in patients with systemic lupus erythematosus correlates with an increased ratio of interleukin-10:interferon-γ - secreting cells in the peripheral blood. Arthritis Rheum 39:379-385, 1996
48. Rengaraju M, Gray JD, Horwitz DA, Kubin M, Trinchieri G: Increased spontaneous IL-10 production and decreased mitogen-induced IFNγ and TNFα production in untreated patients with SLE; role of CD8+ T cells. Lupus 4 (suppl 2):82, 1995
49. Mosmann TR: Properties and functions of interleukin-10. Adv Immunol 56:1-50, 1994
50. Ding L, Shevach EM: IL-10 inhibits mitogen-induced T cell proliferation by selectively inhibiting macrophage costimulatory function. J Immunol 148:3133-3139, 1992
51. De Waal Malefyt R, Yssel H, de Vries JE: Direct effect of IL-10 on subsets of human CD4+ T cell clones and resting T cells: specific inhibition of IL-2 production and proliferation. J Immunol 150:4754-4765, 1993
52. Kaneoka H, Perez-Rojas G, Sasasuki T, Benike CJ, Engleman EG: Human T lymphocyte proliferation induced by a pan-T cell monoclonal antibody (anti-Leu 4): heterogeneity of response is a function of monocytes. J Immunol 131:158-164, 1983
53. Smolen JS, Chused TM, Leisersun WM, Reeves JP, Alling D, Steinberg AD: Heterogeneity of immunoregulatory T-cell subsets in systemic lupus erythematosus. Am J Med 72:783-790, 1982
54. Bakke AC, Kirkland PA, Kitridou RC, Quismorio FP Jr, Rea T, Ehresmann GR, Horwitz DA: T lymphocyte subsets in systemic lupus erythematosus: correlations with corticosteroid therapy and disease activity. Arthritis Rheum 26:745-750, 1983
55. Yamada H, Martin PJ, Bean MA, Braun MP, Beatty PG, Sadamoto K, Hansen JA: Monoclonal antibody 9.3 and anti-CD11 antibodies define reciprocal subsets of lymphocytes. Eur J Immunol 15:1164-1168, 1985
56. McCune WJ, Golbus J, Zeldes W, Bohlke P, Dunne R, Fox DA: Clinical and immunologic effects of monthly administration of intravenous cyclophosphamide in severe systemic lupus erythematosus. N Engl J Med 318:1423-1431, 1988
57. Klinman DM: B cell abnormalities characteristic of systemic lupus erythematosus. In, Dubois' Lupus Erythematosus. Fourth edition. Philadelphia, Lea & Febiger, 1993
58. Tovar Z, Dauphinee MJ, Talal N: Defective induction of T-cell help and natural killing following anti-CD3 stimulation of autoimmune lymphocytes. J Autoimmun 1:327-337, 1988
59. Stekman IL, Blasini AM, Leon-Ponte M, Baroja ML, Abadi I, Rodriguez MA: Enhanced CD3-mediatcd T lymphocyte proliferation in patients with systemic lupus erythematosus. Arthritis Rheum 34:459-467, 1991
60. Martorell J, Font J, Rojo I, Vilella R, Ingelmo M, Vives J: Responsiveness of systemic lupus erythematosus T cells to signals provided through LCA T200 (CD45) and T1 (CD5) antigens. Clin Exp Immunol 78:172-176, 1989
61. Venza-Teti D, Misefari A, Sofo V, Fimiani V, La Via MF: Interaction between prostaglandins and human T-lymphocytes: effect of PGE2 on E-receptor expression. Immunopharmacology 2:165-171, 1980
62. Gordon D, Bray M, Morley J: Control of lymphokine secretion by prostaglandins. Nature 262:401-402, 1976
63. Baker PE, Fahey JV, Munck A: Prostaglandin inhibition of T-cell proliferation is mediated at two levels. Cell Immunol 61:52-61, 1981
64. Rappaport RS, Dodge GR: Prostaglandin E inhibits the production of human interleukin 2. J Exp Med 155:943-948, 1982
65. Rouzer CA, Scott WA, Kempe J, Cohn ZA: Prostaglandin synthesis by macrophages requires a specific receptor-ligand interaction. Proc Natl Acad Sci U S A 77:4279-4282, 1980
66. Cruchaud A, Despont JP, Roth A, Dayer JM: Phagocytosis, bactericidal capacity, and PGE2 production of monocytes in systemic lupus erythematosus and rheumatoid arthritis. Diagn Immunol 2:203-212, 1984
67. Takei M, Kang H, Tomura K, Amaki S, Hirata M, Karasaki M, Sawada S, Amaki I: Aberration of monokine production and monocyte subset in patients with systemic lupus erythematosus. J Clin Lab Immunol 22:169-173, 1987
68. Sunder-Plassmann R, Majdic O, Knapp W, Heiter W: In vitro and in vivo activated T cells display increased sensitivity to PGE2. Cell Immunol 138:289-299, 1991
69. Strassmann G, Patil Koota V, Finkelman F, Fong M, Kambayashi T: Evidence for the involvement of interleukin 10 in the differential deactivation of murine peritoneal macrophages by prostaglandin E2. J Exp Med 180:2365-2370, 1994
70. Tripp CS, Beckerman KP, Unanue ER: Immune complexes inhibit antimicrobial responses through interleukin-10 production: effects in severe combined immunodeficient mice during Listeria infection. J Clin Invest 95:1628-1634, 1995
71. Kubin M, Kamoun M, Trinchieri G: Interleukin 12 synergizes with B7/CD28 interaction in inducing efficient proliferation and cytokine production of human T cells. J Exp Med 180:211-222, 1994
72. Tsokos GC, Kovacs B, Sfikakis PP, Theocharis S, Vogelgesang S, Via CS: Defective antigen-presenting cell function in patients with systemic lupus erythematosus: role of the B7-1 (CD80) costimulatory molecule. Arthritis Rheum 39:600-609, 1996
73. Garcia Cozar FJ, Molina IJ, Cuadrado MJ, Maarubayashi M, Pena J, Santamaria M: Defective B7 expression on antigen-presenting cells underlying T cell activation in systemic lupus erythematosus patients. Clin Exp Immunol 104:72-79, 1996
74. Damle NK, Linsley PS, Ledbetter JA: Direct helper T cell-induced B cell differentiation involves interaction between T cell antigen CD28 and B cell activation antigen B7. Eur J Immunol 21:1277-1282, 1991
75. Dohlsten M, Hedlund G, Lando PA, Trowsdale J, Altmann D, Patarroyo M, Fischer H, Kalland T: Role of the adhesion molecule ICAM-1 (CD54) in staphylococcal enterotoxin-mediated cytotoxicity. Eur J Immunol 21:131-135, 1991
76. Linsley PS, Brady W, Urnes M, Grosmaire LS, Damle NK, Ledbetter JA: CTLA-4 is a second receptor for the B cell activation antigen B7. J Exp Med 174:561-569, 1991
77. Tohma S, Hirohata S, Lipsky PE: The role of CD11a/CD18-CD54 interactions in human T cell-dependent B cell activation. J Immunol 146:492-499, 1991
78. Azuma M, Cayabyab M, Buck D, Phillips JH, Lanier LL: CD28 interaction with B7 costimulates primary allogeneic proliferative responses and cytotoxicity mediated by small, resting T lymphocytes. J Exp Med 175:353-360, 1992
79. Azuma M, Cayabyab M, Phillips JH, Lanier LL: Requirements for CD28-dependent T cell-mediated cytotoxicity. J Immunol 150: 2091-2101, 1993
80. Stohl W, Elliott JE, Linsley PS: Human T cell-dependent B cell differentiation induced by Staphylococcal superantigens. J Immunol 153:117-127, 1994
81. Takeuchi T, Amano K, Sekine H, Koide J, Abe T: Upregulated expression and function of integrin adhesive receptors in systemic lupus erythmatosus patients with vasculitis. J Clin Invest 92:3008-3016, 1993
82. Richardson BC, Strahler JR, Pivirotto TS, Quddus J, Bayliss GE, Gross LA, O'Rourke KS, Powers D, Hanash SM, Johnson MA: Phenotypic and functional similarities between 5-azacytidine-treated T cells and a T cell subset in patients with active systemic lupus erythematosus. Arthritis Rheum 35:647-662, 1992
83. Freedman AS, Freeman GJ, Rhynhart K, Nadler LM: Selective induction of B7/BB-1 on interferon-gamma stimulated monocytes: a potential mechanism for amplification of T cell activation through the CD28 pathway. Cell Immunol 137:429-437, 1991
84. Gimmi CD, Freeman GJ, Gribben JG, Sugita K, Freedman AS, Morimoto C, Nadler LM: B-cell surface antigen B7 provides a costimulatory signal that induces T cells to proliferate and secrete interleukin 2. Proc Natl Acad Sci U S A 88:6575-6579, 1991
85. Sfikakis PP, Oglesby R, Sfikakis P, Tsokos GC: B7/BB1 provides an important costimulatory signal for CD3-mediated T lymphocyte proliferation in patients with systemic lupus erythematosus (SLE). Clin Exp Immunol 96:8-14, 1994
86. Brinchmann JE, Dobloug JH, Heger BH, Haaheim LL, Sannes M, Egeland T: Expression of costimulatory molecule CD28 on T cells in human immunodeficiency virus type 1 infection: functional and clinical correlations. J Infect Dis 169:730-738, 1994
87. Landay AL, Mackewicz CE, Levy JA: An activated CD8 + T cell phenotype correlates with anti-HIV activity and asymptomatic clinical status. Clin Immunol Immunopathol 69:106-116, 1993
88. Harding FA, McArthur JG, Gross JA, Raulet DH, Allison JP: CD28-mediated signalling co-stimulates murine T cells and prevents induction of anergy in T-cell clones. Nature 356:607-609, 1992
89. Emlen W, Niebur J, Kadera R: Accelerated in vitro apoptosis of lymphocytes from patients with systemic lupus erythematosus. J Immunol 152:3685-3692, 1994
90. Cerdan C, Martin Y, Courcoul M, Brailly H, Mawas C, Birg F, Olive D: Prolonged IL-2 receptor alpha/CD25 expression after T cell activation via the adhesion molecules CD2 and CD28: demonstration of combined transcriptional and post-transcriptional regulation. J Immunol 149:2255-2261, 1992
91. Bierer BE, Schreiber SL, Burakoff SJ: The effect of the immuno-suppressant FK-506 on alternate pathways of T cell activation. Eur J Immunol 21:439-445, 1991
92. Alvarado C, Alcocer Varela J, Llorente L, Richaud Patin Y, Cerbon M, Alarcon Segovia D: Effect of CD28 antibody on T cells from patients with systemic lupus erythematosus. J Autoimmun 7:763-773, 1994
93. Alcocer-Varela J, Alarcon-Segovia D: Decreased production and responsiveness to interleukin 2 by cultured lymphocytes from patients with systemic lupus erythematosus. J Clin Invest 69:1388-1392, 1982
94. Monostori E, Desai D, Brown MH, Cantrell DA. Crumpton MJ: Activation of human T lymphocytes via the cD2 antigen results in tyrosine phosphorylation of T cell antigen receptor zeta chains. J Immunol 144:1010-1014, 1990
95. Stohl W, Crow MK: Inhibition by anti-CD2 monoclonal antibodies of anti-CD3-induced T cell-dependent B cell activation. Cell Immunol 130:257-270, 1990
96. Ohno H, Nakamura T, Yagita H, Okumura K, Taniguchi M, Saito T: Induction of negative signal through CD2 during antigenspecific T cell activation. J Immunol 147:2100-2106, 1991
97. Barlow AK, Like AA: Anti-CD2 monoclonal antibodies prevent spontaneous and adoptive transfer of diabetes in the BB/Wor rat. Am J Pathol 141:1043-1051, 1992
98. Jung S, Toyka K, Hartung HP: Suppression of experimental autoimmune encephalomyelitis in Lewis rats by antibodies against CD2. Eur J Immunol 25:1391-1398, 1995
99. Ohtsuka K, Gray JD, Stimmler M, Horwitz DA: Production of transforming growth factor β1 by lymphocytes in human systemic lupus erythematosus (abstract). Arthritis Rheum 39 (suppl 9): S251, 1996